$0.19
-0.01 (-5.05%)
Open$0.20
Previous Close$0.20
Day High$0.21
Day Low$0.19
52W High$19.20
52W Low—
Volume—
Avg Volume2.29M
Market Cap2.07M
P/E Ratio—
EPS$-5.81
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+25,355.5% upside
Current
$0.19
$0.19
Target
$48.34
$48.34
$29.39
$48.34 avg
$58.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.75M | 1.85M | 1.56M |
| Net Income | -488,923 | -548,272 | -518,591 |
| Profit Margin | -27.9% | -29.7% | -33.3% |
| EBITDA | -843,788 | -899,520 | -655,593 |
| Free Cash Flow | -343,922 | -223,177 | -234,743 |
| Rev Growth | +4.0% | +6.5% | +13.9% |
| Debt/Equity | 0.91 | 0.97 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |